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and no reports of disease transmission
were received from any other recipi-
ents of organs from this donor. In
addition, the patient had no history of
receiving infusions of holistic or alter-
native medicines.
The organism was initially
detected in the aerobic Bact/Alert
blood culture system (bioMérieux,
Inc., Durham, NC) after 72 h incuba-
tion at 35°C. Presumptive identifica-
tion of the pleomorphic gram-positive
bacillus as Streptomyces sp. was based
on phenotypic characterization by
using standard conventional tests and
cellular fatty acid analysis. Species
identification was determined by
DNA sequencing of the 16S rRNA
gene. DNA sequencing reactions were
performed with the Tag Dye Deoxy
Terminator Cycle Sequencing Kit
(Applied Biosystems, Inc., Foster
City, CA), and data were generated
with an ABI 377 automated instru-
ment. The sequence data were assem-
bled, edited, and compared with
published sequences for the 16S
rRNA gene of S. bikiniensis (2).
The genus Streptomyces belongs to
the order Actinomycetales, which
includes  Mycobacterium,  Nocardia,
and  Actinomyces.  Streptomyces  are
gram-positive, extensively branched,
filamentous bacteria that form aerial
hyphae with chains of spores. Their
natural habitat is soil, and each species
has a defined geographic distribution.
None are common in the United
States. With the exception of speci-
mens from actinomycotic mycetoma,
the isolation of Streptomyces from
clinical specimens frequently is con-
sidered laboratory contamination (3).
Rare cases of clinical disease attrib-
uted to Streptomyces have been pub-
lished, including bloodstream
infection (1,4) and focal invasive
infections (5–9). Streptomyces was not
the only potential pathogen isolated
from some of the clinical specimens in
these studies. 
Scant data are available on effec-
tive treatment of Streptomyces infec-
tion. Mycetoma caused by Strep-
tomyces is often treated with penicillin,
sulfonamides, or tetracycline; how-
ever, the cure rate is low. The recom-
mended duration of therapy is lengthy
(up to 10 months). Isolates of S. gri-
seus referred to the Centers for Disease
Control and Prevention were fre-
quently resistant to ampicillin (80%),
sulfamethoxazole (43%), cotrimox-
azole (29%), and ciprofloxacin (57%)
(10). Resistance to doxycycline (19%)
and minocycline (10%) was lower.
Vancomycin susceptibility was not
tested. Resistance patterns must be
interpreted cautiously because Strepto-
myces can synthesize antibiotics,
potentially confounding results of in-
vitro susceptibility testing. 
The patient described in this report
had no signs or symptoms of infection.
The transient fever that prompted the
first blood culture was probably due to
the methotrexate infusion and not
infection with S. bikiniensis. That the
fever was of short duration despite
persistently positive blood cultures
supports this conclusion. The potential
for causing minimal symptoms may
contribute to assignment of Streptomy-
ces as a contaminant. Clinical correla-
tion is difficult if the infection is
silent.  Streptomyces isolated from
blood cultures should not be dismissed
as contaminants without careful con-
sideration of the clinical situation; the
isolation of Streptomyces from repeat
blood cultures strongly suggests a
pathogenic role. 
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Drug-Resistant 
Mycobacterium 
tuberculosis among 
New Tuberculosis 
Patients, Yangon, 
Myanmar
To the Editor: Spread of drug-
resistant tuberculosis (TB) and disas-
trous rates of HIV-TB co-infection
pose serious threats to TB-control pro-
grams around the world (1). The
World Health Organization/Interna-
tional Union Against Tuberculosis and
Lung Diseases urges all national TB
programs to practice the Directly
Observed Treatment-Short Course
(DOTS) strategy as well as to closely
monitor the patterns and trends of
anti-TB drug resistance (2). Such data
allow an assessment of the quality of
TB control, help forecast future trendsEmerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 275
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of drug-resistance, and serve  as
guidelines for suitable therapy. 
In 1997 the national TB programs
of Myanmar introduced DOTS in the
capital city, Yangon, which has
approximately 5 million inhabitants.
All new case-patients in national TB
program clinics are routinely treated
with isoniazid, rifampicin, ethambu-
tol, and pyrazinamide without drug
susceptibility testing of Mycobacte-
rium tuberculosis. However, isolates
from previously treated patients are
frequently tested for drug susceptibil-
ity, and treatment is guided by the
results. Myanmar is one of the 22
countries that account for 80% of the
world’s new TB cases (3), yet little is
known about drug-resistant TB in that
country. We report on the pattern of
drug resistance to first-line anti-TB
drugs among M. tuberculosis com-
plex isolates from Zone 1 TB center in
Yangon, which receives approxi-
mately 70% of the national TB pro-
grams’ TB cases in Yangon. Of the
864 patients who attended this center
in July 2000, a total of 202 were diag-
nosed as having pulmonary TB on the
basis of medical history, clinical signs,
two smear-positive sputum samples,
and chest x-ray, if necessary. Approxi-
mately half of these cases were new
pulmonary TB patients, i.e. smear-
positive patients who had never been
treated previously. Sputum specimens
from 72 consecutive, new pulmonary
TB case-patients were injected on
Ogawa medium according to standard
procedure (2); samples from 68
patients (94%) were culture-positive.
Isolates from 17 patients were lost for
further study because of bacterial con-
tamination and failure to grow on sub-
culture. Thus, isolates from 51
patients were available for the current
investigation. By using the AccuProbe
Mycobacterium tuberculosis complex
test (Gen-Probe, San Diego, CA), all
isolates were found to belong to the M.
tuberculosis complex. Testing of iso-
lates for susceptibility to isoniazid,
rifampicin, ethambutol, and strepto-
mycin was performed by using the
standard Mycobacteria Growth Indi-
cator Tube manual system, as recom-
mended by the manufacturer (Becton
Dickinson, Sparks, MD). The Wayne
assay (4), which measures the activity
of pyrazinamidase, was used for
pyrazinamide susceptibility testing.
This assay was performed according
to World Health Organization guide-
lines for speciation within the M.
tuberculosis  complex (5). Eighteen
isolates (35%) were resistant to any
one of the five anti-TB drugs. Thirteen
isolates (26%) were resistant to iso-
niazid, nine isolates (18%) to strepto-
mycin, four isolates (8%) to
ethambutol, one isolate (2%) to
rifampicin, and one isolate (2%) to
pyrazinamide. Only one isolate (2.0%)
was multidrug resistant (MDR)-M.
tuberculosis, i.e., resistant to both iso-
niazid and rifampicin. 
The World Health Organization/
International Union Against Tubercu-
losis and Lung Diseases global survey
in the year 2000 (6) showed that the
prevalence of resistance to at least one
anti-TB drug (isoniazid, rifampicin,
ethambutol, and streptomycin) among
new cases ranged from 1.7% to
36.9%. In our study, 33.3% of the iso-
lates from new pulmonary TB patients
were resistant to at least one of these
drugs. The finding shows that a rela-
tively high frequency of drug resis-
tance exists among our patients. If
pyrazinamide is included in the calcu-
lation, the proportion of drug resis-
tance among our patients is 35.3%. In
1994, Ti et al. reported that MDR-TB
represented 1.25% of the isolates from
400 patients with newly diagnosed
pulmonary TB who attended the Zone
1 TB center (7). When one considers
the corresponding figure of 2.0% in
the current material, frequency of
MDR-TB in Yangon does not seem to
have changed dramatically during the
period 1994–2000. MDR-TB among
new patients appears to be less com-
mon in Yangon than in big cities in
Thailand (4.2%) (8) and in China
(4.5%) (6). However, a substantial
number of our isolates (15.7%) were
resistant to two or more anti-TB drugs,
in most cases to both isoniazid and
streptomycin (9.8%). In the 1994
report by Ti et al., mono-resistance to
streptomycin (6.5%) or isoniazid
(5.8%) predominated, and 2.0% of the
isolates were resistant to both iso-
niazid and streptomycin (7). Our
present results, therefore, indicate that
drug resistance is an imminent threat
to TB-control efforts in Yangon,
although MDR-TB still seems to be
relatively rare. 
The low number of MDR cases in
our study could partly be explained by
demographic features of the studied
population, which is composed pre-
dominately of people residing in satel-
lite townships of Yangon. These
townships usually attract young peo-
ple who immigrate to Yangon from
village areas. These immigrants are
less likely to have previous exposure
to TB than the permanent population
since the prevalence of TB infection is
lower in rural than in urban areas (9).
Moreover, population densities of the
satellite townships are 2- to 10-fold
lower than in inner Yangon city
(Myanmar Central Statistical Organi-
zation). The high number of drug-
resistance cases among our patients
with newly detected TB could be
explained by an undisclosed past
exposure to anti-TB drugs. The case
detection rate reported by the Myan-
mar national TB programs is 48% (3),
suggesting that many TB patients
receive their treatment elsewhere. A
World Health Organization report (10)
indicates that >80% of the health-care
expenditure in Myanmar and other
Asian countries such as India, Viet-
nam, and Cambodia is spent in the pri-
vate sector. In such countries, poor
treatment practices in the private sec-
tor may lessen the impact of the
DOTS implemented by national TB
programs and contribute to a growing
incidence of drug-resistant TB. This
problem will undoubtedly be escalated
by the availability  of anti-TB drugs
without prescription. HIV-TB co-
infection often results in increased fre-
quency of adverse drug effects, which
may reduce compliance and increase
induction of drug resistance. AlthoughLETTERS
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the prevalence of HIV positivity
among our patients is unknown, a pre-
liminary study from Yangon shows
that the prevalence of drug-resistant
TB among HIV-seropositive and -
seronegative patients is the same
(pers. comm., Myanmar national TB
programs]. To our knowledge, this
report is the first to describe drug-
resistant patterns in M. tuberculosis
isolates from Myanmar.
Acknowledgments
We thank Elling Ulvestad for provid-
ing excellent laboratory facilities and
Grete Hopland and Synnøve Simonnes for
technical advice. 
This study was supported by the Uni-
versity of Bergen and Haukeland Univer-
sity Hospital, Bergen, Norway.
Sabai Phyu,* Ti Ti,† Roland Jureen,* 
Thandar Hmun,† Hlaing Myint,† 
Aye Htun,† Harleen M.S. Grewal,* 
and Bjarne Bjorvatn*  
*University of Bergen, Bergen, Norway; and
†National TB Programme, Yangon, Myanmar
References
    1. World Health Organization/Stop TB part-
nership. Stop TB annual report 2001.
Geneva: The Organization; 2001.
  2. De Kantor IN, Kim SJ, Frieden T, Laszlo
A, Luelmo F, Norval P-Y, et al. Laboratory
services in tuberculosis control. Geneva:
World Health Organization; 1998.
  3. World Health Organization. Global tuber-
culosis control: surveillance, planning,
financing. Communicable diseases.
Geneva: The Organization; 2002.
  4. Wayne  LG.  Simple pyrazinamidase and
urease test for routine identification of
mycobacteria. Am Rev Respir Lung Dis
1974;109:147–51.
  5. Grange JM, Yates M, de Kantor IN. Guide-
lines for speciation within the Mycobacte-
rium  tuberculosis complex. 2nd ed.
Geneva: World Health Organization; 1996.
    6. The World Health Organization/Interna-
tional Union Against Tuberculosis and
Lung Diseases global project on anti-tuber-
culosis drug resistance surveillance. Anti-
tuberculosis drug resistance in the world–
report no. 2, prevalence and trends.
Geneva: The Organization; 2000. 
  7. Ti T, Aye T, Mu SH, Myint KM, Min A,
Maung T, et al. A random sample study of
initial drug resistance among tuberculosis
cases in Yangon, Myanmar. Proceedings of
the Myanmar Health Research Congress.
1995 Dec; Yangon, Myanmar. Yangon,
Myanmar: Department of Medical
Research, Ministry of Health; 1995. 
  8. Riantawan P, Punnotok J, Chaisuksuwan R,
Pransujarit V. Resistance of Mycobacte-
rium tuberculosis to antituberculosis drugs
in the central region of Thailand, 1996. Int
J Tuberc Lung Dis 1998;2:616–20.
  9. Roelsgaard E, Iversen E, Bløcher C. Tuber-
culosis in tropical Africa. An epidemiologi-
cal study. Bull World Health Organ
1964;30:459–518.
10. Health System: Improving performance.
The world health report 2000. Geneva:
World Health Organization; 2000.
Address for correspondence: Sabai Phyu, Dept.
of Microbiology & Immunology, The Gade
Institute, University of Bergen, Haukeland Uni-
versity Hospital, 5021 Bergen, Norway; fax: 47
55974979; e-mail: sabai.phyu@cih.uib.no
Pneumocystis 
carinii vs. 
Pneumocystis 
jiroveci: Another 
Misnomer 
(Response to 
Stringer et al.)
To the Editor: The proposal by
Stringer et al. to change the name of
Pneumocystis carinii found in humans
to Pneumocystis jiroveci requires criti-
cal consideration (1). First, their ratio-
nale for the choice of Jírovec is not
compelling. Principle III of the Inter-
national Code of Botanical Nomencla-
ture (ICBN) states: “the nomenclature
of a taxonomic group is based upon
priority of publication” (2). Jírovec’s
publication in 1952 was not the first to
report  P. carinii infection in human
lungs. In 1942, two Dutch investiga-
tors, van der Meer and Brug,
described  P. carinii as the infecting
organism in a 3-month-old infant with
congenital heart disease and in 2 of
104 autopsy cases (a 4-month-old
infant and a 21-year-old adult) (3).
Their description, photomicrographs,
and drawings of P. carinii are
unequivocal. They also described the
typical “honeycomb” patterns in alve-
oli. In 1951, Dr. Josef Vanek at Karls-
Universität in Praha, Czechoslovakia,
reported his study of lung sections
from 16 children with interstitial
pneumonia and demonstrated that the
disease was caused by P. carinii (4).
Vanek notes in his report, “In man the
parasite was for the first time estab-
lished as a cause of pneumonia in a
child by G. Meer and S. L. Brug
(1942).” In 1952, Jírovec reported P.
carinii as the cause of interstitial plas-
macellular pneumonia in neonates (5).
A year later, in a coauthored publica-
tion, Vanek, Jírovec, and J. Lukes
acknowledged and referenced the ear-
lier reports of van der Meer and Brug
and Vanek (6). If principle III is to be
followed, as well as fairness to the
investigators, both van der Meer and
Brug and Vanek hold priority over
Jírovec, assuming the designation of
the species name should be based on
the name of the first person to dis-
cover P. carinii in humans.
The nomenclature of P. carinii has
actually been fraught with errors from
the beginning. In the earliest publica-
tions, Carlos Chagas and Antonio Car-
ini mistook the organism for stages in
the life cycle of trypanosomes. Chagas
placed it in a new genus, Schizotry-
panum (7,8). In 1912, Delanoë and
Delanoë at the Pasteur Institute in
Paris published the first description of
the organism as a new entity unrelated
to trypanosomes (9). They proposed
the name “Pneumocystis carinii” as a
tribute to Carini. The Delanoë paper
has remained unchallenged as the
original description of P. carinii. Both
Chagas and Carini later acknowledged
their errors and the validity of the Del-
anoës’ conclusion. By current ICBN
principles,  P. carinii is acceptable
nomenclature because the authors of
the first publication proposed the
name of Carini, rather than their own.
In addition, changing the name to
P. jiroveci will create confusion in
clinical medicine where the name P.
carinii has served physicians and
microbiologists well for over half a